8-K: Medicus Pharma Dismisses Auditor EisnerAmper Amidst Going Concern Doubts and Internal Control Weaknesses; Engages KPMG

Medicus Pharma Ltd. has dismissed its independent auditor EisnerAmper LLP and engaged KPMG LLP, following EisnerAmper's report raising substantial doubt about the company's ability to continue as a going concern and identifying material weaknesses in internal controls.

Summary

• Medicus Pharma Ltd. dismissed EisnerAmper LLP as its independent registered public accounting firm on June 3, 2025, a decision recommended by the Audit Committee and approved by the Board of Directors.
• EisnerAmper's report for the year ended December 31, 2024, included a 'going concern' paragraph, citing negative cash flows from operating activities and incurred operating losses that raise substantial doubt about the company's ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified for the fiscal year ended December 31, 2024, and the quarter ended March 31, 2025.
• These weaknesses include a lack of precision in reviewing materials for recording transactions in accordance with U.S. GAAP and a lack of formalized IT system policies, covering security, cybersecurity, centrally managed security patches, antivirus/malware protection, and user access.
• Despite the identified material weaknesses, management stated they did not believe these issues affected the accuracy of the Company's financial statements for the reporting periods ended December 31, 2024, and March 31, 2025, and no restatement of previously reported financial statements occurred.
• On June 4, 2025, the Board approved the engagement of KPMG LLP as the new independent registered public accounting firm to audit the Company's financial statements for the year ending December 31, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the 'going concern' qualification, indicating significant financial distress, and the disclosure of material weaknesses in internal controls, which raises concerns about financial reporting reliability and operational integrity. While a new auditor has been engaged, the underlying issues remain prominent.

Positives

• The company has engaged a new auditor, KPMG LLP, which may signal a proactive step towards addressing audit-related concerns and strengthening financial oversight.
• No disagreements on accounting principles, financial statement disclosure, or auditing scope/procedure were reported between the Company and the dismissed auditor, EisnerAmper LLP.
• The identified material weaknesses in internal control did not result in the restatement of any previously reported financial statements, suggesting that past financial reports remain accurate despite control deficiencies.

Negatives

• EisnerAmper LLP's report included a 'going concern' qualification for the year ended December 31, 2024, indicating substantial doubt about Medicus Pharma Ltd.'s ability to continue operations due to negative cash flows from operating activities and incurred operating losses.
• The company identified material weaknesses in its internal control over financial reporting, specifically regarding the lack of precision in reviewing materials for GAAP recording and the absence of formalized IT system policies (including security, cybersecurity, and user access).
• The existence of material weaknesses raises concerns about the reliability of the company's financial reporting and its ability to safeguard information and assets.

Risks

• Going Concern Uncertainty: Substantial doubt exists about the Company's ability to continue as a going concern due to persistent negative cash flows from operating activities and incurred operating losses, which could impact its operational viability and access to future financing.
• Internal Control Weaknesses: Material weaknesses in internal control over financial reporting, particularly concerning GAAP recording precision and IT system environment policies, pose risks of financial misstatement, data breaches, and operational inefficiencies.
• Reputational Damage: The disclosure of a 'going concern' qualification and material weaknesses could negatively impact investor confidence, market perception, and the company's ability to attract capital or partners.

Future Outlook

The document does not provide explicit forward-looking statements or guidance beyond the engagement of a new auditor for the upcoming fiscal year. The 'going concern' qualification implies a critical need for management to address financial sustainability and operational improvements.

Management Comments

• "The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company experienced negative cash flows from operating activities and has incurred operating losses that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty." (Quoting EisnerAmper's report, reflecting management's financial situation)
• Management did not believe that the identified material weaknesses had any effect on the accuracy of the Company's financial statements for the reporting periods ended December 31, 2024, and March 31, 2025.

Industry Context

This filing is specific to Medicus Pharma Ltd.'s corporate governance and financial reporting practices. While auditor changes occur across industries, the specific reasons (going concern, material weaknesses in IT controls) highlight challenges that can be particularly acute for smaller or emerging companies in the pharmaceutical or biotech sector, which often require significant capital and robust internal controls for R&D, regulatory compliance, and financial stability.

Comparison to Industry Standards

• The 'going concern' qualification is a significant red flag, indicating that Medicus Pharma Ltd. is not meeting the financial stability standards typically expected of publicly traded companies, especially compared to established pharmaceutical or biotech firms that generally demonstrate positive cash flows or clear paths to profitability.
• The identified material weaknesses in internal control over financial reporting, particularly concerning IT security and GAAP recording precision, suggest a deficiency in corporate governance and operational controls that is below the robust standards expected for companies handling sensitive financial data and operating in a highly regulated industry like pharmaceuticals.
• While auditor changes happen, a change following a 'going concern' opinion and material weaknesses is often viewed more critically than routine rotations, contrasting with best practices where auditor changes are part of a healthy governance cycle without such underlying issues.

Corporate Governance

Stakeholder Impact

• Shareholders: Face increased risk due to the 'going concern' uncertainty and potential negative impact on share price. The material weaknesses could also erode confidence in the accuracy and reliability of financial reporting.
• Creditors: May view the company as a higher credit risk due to financial instability and internal control issues, potentially affecting lending terms or access to credit.
• Employees: Potential uncertainty regarding the company's long-term viability and job security due to the 'going concern' qualification.
• Customers/Suppliers: May experience concerns about the company's stability, potentially affecting business relationships, contract terms, or willingness to engage in long-term agreements.

Next Steps

• KPMG LLP will audit the Company's financial statements for the year ending December 31, 2025.
• Management will need to address the issues leading to the 'going concern' qualification and the identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

Keywords

Medicus Pharma, auditor change, Form 8-K, going concern, material weaknesses, internal control, financial reporting, EisnerAmper, KPMG, NASDAQ, pharmaceutical, biotech